

Scientific programme – overview

Tuesday 21 October		Wednesday 22 October		
ROOM ABC		ROOM A	ROOM B	ROOM C
		Workshop 1 Animal models in drug development	Workshop 2 Pharmacogenomics-where are we now?	Workshop 3 Paedatric oncology
		Coffee Break		
		Workshop 4 Phase 0 trials-are they necessary?	Workshop 5 Targeting CYP pathway	Workshop 6 Design and conduct of phase II trials for targeted agents
		Lunch/Poster session		
		Keynote Lecture RECIST 1.1		
		Plenary session 2 Proffered papers		
		Coffee Break		
		Plenary session 3 Molecular targets-state of the science B		

Posters

Angiogenesis
 Animal models
 Biomarkers
 Chemoprevention
 Drug delivery
 Drug screening
 Heat shock proteins
 Hormonal agents
 Metastasis and invasion
 Natural products and marine compounds
 Paediatric - early drug development
 Pharmacogenomics
 Phase II
 PI3Kinase
 Proteasome

Thursday 23 October		Friday 24 October	
ROOM ABC		ROOM ABC	
08.00	Plenary session 4 Targeting autophagic pathways	08.00	Plenary session 8 RNA based technologies for target identification, validation and treatment
09.45	Coffee Break	09.45	Coffee Break
10.15	Plenary session 5 Molecular targets-state of the science C	10.15	Plenary session 9 Imaging molecular targets
12.00		12.00	
Lunch/Poster session		Lunch/Poster session	
14.30	Plenary session 6 Proffered papers	14.00	Plenary session 10 Challenges in the development of antibodies and antibody conjugates
16.00		15.45	
	Coffee Break		Closing ceremony
16.30	Plenary session 7 Targeting protein translation and protein-protein interaction in cancer	15.50	
18.15			
Get together Party			

Posters

Apoptosis, necrosis, autophagy
Aurora kinase
Cyclins and CDK's
Gene therapy and antisense approaches
Her
mTOR
New molecular targets
Phase I
Polo kinase
Protein - protein interaction
Telomerase - targeting agents
Tubulin - interacting agents

Posters

Antimetabolites
Bioreductive agents
Differentiation
DNA repair
Drug resistance and modifiers
Monoclonal antibodies and targeted toxins/nuclides
Radiation interactive agents
RNA and RNA based technologies
Signal transduction modulators
Topoisomerase inhibitors
Vaccines